Sexually Transmitted Disease (Genital Warts)

Vaccine Development Collaboration Formed

Published in AIDS Weekly, August 5th, 1996

Cantab Pharmaceuticals plc, Cambridge, United Kingdom, and SmithKline Beecham Biologicals Manufacturing s.a. (SBBio), Rixensart, Belgium, announced that the companies have formed a collaboration to develop and market Cantab's TA-GW vaccine for genital warts.

"The interest in this disease area within the pharmaceutical industry is very high," said Paul Haycock, M.D., Cantab. "We have been in discussions with several major companies about TA-GW, but SBBio's experience and commitment to novel vaccine development, both for therapy and prophylaxis, their expertise with new adjuvants, and their specialized global marketing infrastructure combine to make them a highly...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1996-08-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry